| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
89,554,000 |
| Market
Cap: |
2.19(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.02 - $46.03 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,902 |
53,430 |
61,187 |
62,275 |
| Total Sell Value |
$95,737 |
$1,583,155 |
$1,913,663 |
$1,961,404 |
| Total People Sold |
2 |
7 |
8 |
8 |
| Total Sell Transactions |
2 |
10 |
15 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Formela Jean Francois |
Director |
– • – |
2021-04-26 |
4 |
AS |
$84.93 |
$68,454 |
I/I |
(806) |
1,111,770 |
|
105% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-04-13 |
4 |
OE |
$6.83 |
$289,506 |
D/D |
25,937 |
719,305 |
|
- |
|
| Keresty Georgia |
Director |
– • – |
2021-04-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,955 |
4,955 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2021-04-05 |
4 |
AS |
$84.98 |
$67,984 |
I/I |
(800) |
1,112,576 |
|
100% |
|
| Dorsa Caroline |
Director |
– • – |
2021-04-05 |
4 |
AS |
$81.49 |
$616,405 |
D/D |
(7,500) |
5,410 |
|
100% |
|
| Dorsa Caroline |
Director |
– • – |
2021-04-05 |
4 |
OE |
$6.40 |
$48,000 |
D/D |
7,500 |
12,910 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2021-04-01 |
4 |
AS |
$83.00 |
$3,195,661 |
D/D |
(38,209) |
693,368 |
|
99% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-04-01 |
4 |
OE |
$13.40 |
$1,005,049 |
D/D |
71,041 |
707,263 |
|
- |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-04-01 |
4 |
AS |
$80.73 |
$4,160,559 |
D/D |
(50,455) |
162,388 |
|
99% |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-04-01 |
4 |
OE |
$6.83 |
$1,213,537 |
D/D |
97,001 |
178,077 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2021-02-26 |
4 |
S |
$60.29 |
$30,262,716 |
I/I |
(501,945) |
1,113,376 |
|
-153% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-09 |
4 |
AS |
$75.00 |
$2,103,225 |
D/D |
(28,043) |
660,536 |
|
8% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-09 |
4 |
OE |
$6.83 |
$387,384 |
D/D |
56,718 |
688,579 |
|
- |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-02-09 |
4 |
AS |
$75.00 |
$861,675 |
D/D |
(11,489) |
117,920 |
|
8% |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-02-09 |
4 |
OE |
$18.30 |
$384,195 |
D/D |
21,000 |
129,409 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-05 |
4 |
AS |
$67.18 |
$1,552,185 |
D/D |
(22,942) |
631,861 |
|
11% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-05 |
4 |
OE |
$13.40 |
$536,000 |
D/D |
40,000 |
654,803 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-03 |
4 |
AS |
$72.00 |
$4,922,490 |
D/D |
(67,856) |
614,803 |
|
33% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-03 |
4 |
OE |
$13.88 |
$2,069,793 |
D/D |
117,060 |
651,661 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-01 |
4 |
AS |
$63.24 |
$7,032,905 |
D/D |
(109,889) |
565,599 |
|
33% |
|
| Leonard John M. |
President and CEO |
• • – |
2021-02-01 |
4 |
OE |
$6.83 |
$2,737,600 |
D/D |
200,000 |
598,814 |
|
- |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-02-01 |
4 |
AS |
$63.31 |
$3,497,902 |
D/D |
(54,659) |
108,409 |
|
33% |
|
| Rivera Jose E |
EVP, General Counsel |
• – – |
2021-02-01 |
4 |
OE |
$6.83 |
$1,054,620 |
D/D |
109,000 |
113,876 |
|
- |
|
| Cohen Fred E |
Director |
– • – |
2021-01-20 |
4 |
OE |
$13.78 |
$275,600 |
D/D |
20,000 |
30,000 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2021-01-05 |
4 |
S |
$55.86 |
$348,511 |
D/D |
(6,239) |
475,488 |
|
-10% |
|
245 Records found
|
|
Page 6 of 10 |
|
|
0.40 (1.61%) 
